Search
Pemoline
go.drugbank.com/drugs/DB01230ApprovedIllicitWithdrawnIn 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Categories: Heterocyclic Compounds, 1-RingCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThe FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamidePulmonary Tuberculosis resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug
go.drugbank.com/conditions/DBCOND0154352Drugs: PretomanidSynonyms: Pulmonary Tuberculosis resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drugPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.
Mixtures: REAMPLA®, REAMPLA®Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexThioguanine Metabolism Pathway (old)
smpdb.ca/view/SMP0000647Drug metabolismOnce in a cell, thioguanine is converted to thioguanosine monophosphate by hypoxanthine-guanine phosphoribosyltransferase. … The thioguanosine triphosphate metabolite also inhibits Ras-related C3 botulinum toxin substrate 1, a plasma membrane-associated small GTPase that regulates cellular processes, inducing apoptosis in activated
Iobenguane sulfate I-123
go.drugbank.com/drugs/DB09546ApprovedIobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].
Synonyms: Iobenguane sulfate I 123, Iobenguane sulfate I-123Products: i 123 MIBG meta iodobenzylguanidineFish oil
go.drugbank.com/drugs/DB13961ApprovedInvestigationalNutraceuticalFish oil is a component of SMOFLIPID, which was FDA approved in July 2016. … In general, dietary or pharmaceutical intake of these acids is primarily the only way to increase their levels in the human body where they are overall an essential element to dietary health as they have
Mixtures: VINATAL DHA CAPSULA DE GELATINA BLANDA, SmofKabiven N-Plus zentral Emulsion zur InfusionCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFerrous gluconate
go.drugbank.com/drugs/DB14488ApprovedInvestigationalMixtures: Iron II, Alsimine W Vitamins A DSynonyms: Iron(II) gluconate, anhydrous, D-gluconic acid, iron(2+) salt (2:1)Telotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937]
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsLeniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigationalThe FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). … [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates